Drug Profile
Research programme: attention deficit hyperactivity disorder therapies - Nxera Pharma
Alternative Names: Bifemelane hydrochloride; SON-216Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Nxera Pharma
- Class Benzhydryl compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder